Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 9/20 | 0.57 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.57 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086992 | 0.84 | CNR2 (0.61) | EGLN1EGLN3EGLN2CNR2CYSLTR2 | |
| SCHEMBL8247330 | 0.84 | EGLN1 (0.65) | EGLN1EGLN3EGLN2CYSLTR2HIF1A | |
| SCHEMBL8240012 | 0.83 | EGLN1 (0.72) | EGLN1EGLN3EGLN2CYSLTR2HIF1A | |
| SCHEMBL2088512 | 0.82 | EGLN1 (0.51) | EGLN1EGLN3EGLN2CNR2HIF1A | |
| SCHEMBL3513713 | 0.82 | EGLN1 (0.68) | EGLN1EGLN3EGLN2CNR2CYSLTR2 | |
| SCHEMBL2086804 | 0.82 | CNR2 (0.47) | EGLN1CNR2 | |
| SCHEMBL5311750 | 0.81 | EGLN1 (0.69) | EGLN1EGLN3EGLN2CYSLTR2HIF1A | |
| SCHEMBL2085652 | 0.80 | EGLN1 (0.62) | EGLN1EGLN3EGLN2CNR2CYSLTR2 | |
| SCHEMBL3513398 | 0.80 | EGLN1 (0.65) | EGLN1EGLN3EGLN2CNR2CYSLTR2 | |
| SCHEMBL8244832 | 0.80 | EGLN1 (0.81) | EGLN1EGLN3EGLN2CYSLTR2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | claimed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | claimed |
| EP-1991227-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007103905-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | claimed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| WO-2007103905-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885EGLN2 2/4885 |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885EGLN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.